ArticleAnnals of surgical oncology2026
Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChyle leak is a relevant complication after surgery for pancreatic ductal adenocarcinoma (PDAC). Increasing use of multimodal neoadjuvant therapy (NAT) and extended resections may contribute to a higher incidence. This study aimed to describe the incidence of clinically relevant chyle leak and identify its risk factors in patients with PDAC treated with NAT and surgery versus upfront surgery. PATIENTS AND
methodsPatients undergoing PDAC resection between 2014 and 2019 were identified from a prospective institutional database. Clinicopathologic and demographic data were extracted. The primary outcome was clinically relevant chyle leak according to the International Study Group of Pancreatic Surgery (ISGPS). Univariable and multivariable logistic regression were performed to identify associated factors.
resultsA total of 1402 patients were included: 1090 (77.7%) underwent upfront surgery, and 312 (22.3%) received NAT. Pancreatic head resections were performed in 718 (51.2%), distal pancreatectomies in 317 (22.6%), and total pancreatectomies in 367 (26.2%) individuals. Overall, 108 (7.7%) developed clinically relevant chyle leak: 88 (6.3%) grade B and 20 (1.4%) grade C. NAT (odds ratio [OR] 1.45, 95% confidence interval [CI] 1.10-1.91), T stage (pT2/3/4 versus pT0/1, OR 1.53, 95% CI 1.03-2.34), and total pancreatectomy (OR 2.29, 95% CI 1.78-2.96) were associated with any chyle leak. For grade B/C, only NAT was an independent risk factor (OR 2.63, 95% CI 1.74-3.94). Age, resection type, and nodal status were not independent risk factors.
conclusionsNAT is an independent risk factor for clinically relevant chyle leak following PDAC resection. These findings highlight the need for risk-adapted postoperative management and warrant prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.